{"success":true,"data":{"pressRelease":{"id":"16526","rtpr_id":"nPrepMBhxa","ticker":"1295","exchange":"TPEx","all_tickers":["1295"],"title":"SynbioTech To Unveil Microbiome‑Based Platform for Women's Healthy Aging at Vitafoods Europe 2026","author":"PR Newswire","published_at":"2026-05-01T08:00:00.029Z","article_body":"SynbioTech To Unveil Microbiome‑Based Platform for Women's Healthy Aging at\nVitafoods Europe 2026\nPR Newswire\n\nKAOHSIUNG, May 1, 2026\n\nTaiwan Innovators Bring Proven Muscle, Joint, and Kidney Probiotics to Women's\nHealthy Aging\n\nKAOHSIUNG, May 1, 2026 /PRNewswire/ -- SynbioTech, a Taiwan‑based developer\nof probiotic and postbiotic solutions, will present a portfolio of\nmicrobiome‑based ingredients targeting women's healthy aging at Vitafoods\nEurope 2026, to be held May 5–7 at Fira Barcelona Gran Via in Barcelona,\nSpain. The company will exhibit at Booth 3G236 and showcase clinical and\npreclinical evidence across applications including muscle maintenance, gut\nhealth, mobility, and metabolic balance for women's healthy aging support.\n\nAs women's health shifts from narrow claims to holistic vitality, brands are\nplacing greater emphasis on long-term strength, function, and quality of life.\n\nMarket signals already reflect this trend. According to Future Market\nInsights, the global healthy aging supplement market is estimated to grow from\nUSD 1.41 billion in 2024 to USD 2.16 billion by 2034, while Grand View\nResearch reports that the global women's health segment generated USD 38.30\nbillion in 2024 and is expected to reach USD 51.76 billion by 2030. For\nbrands, the opportunity lies at the intersection of these two trends: women's\nhealthy aging.\n\nMicrobiome Solutions for the Many Dimensions of Women's Aging\n\nAs women's health broadens beyond single-function positioning, brands are\nlooking for product concepts that reflect how wellness needs are connected.\nMuscle health, digestion, metabolism, intimate care, and mobility are often\ndiscussed separately, but for aging consumers, they increasingly shape the\nsame goal: staying active and independent for longer.\n\nThis is where microbiome science is gaining relevance. Probiotics and\npostbiotics are no longer viewed only through the lens of digestive health;\nthey are being explored for broader roles across the gut–muscle axis,\nmicrobial balance, and metabolic wellness.\n\nTWK10®: From Sports Nutrition to Active Aging\n\nA key focus of SynbioTech's showc ase will be TWK10®, the company's\nLactiplantibacillus plantarum strain known for its work in sports and active\nnutrition. TWK10® is gaining relevance in active aging, where maintaining\nmuscle mass, strength, mobility, and independence becomes increasingly\nimportant. Backed by 9 clinical studies and 27 publications, TWK10® has\ndemonstrated measurable outcomes in human trials, including:\n* 3% increase in muscle mass,\n* 13% improvement in grip strength,\n* 16.8% improvement in mobility and agility\n* 51% increase in endurance and stamina\nThe strain also doubles total amino acid absorption, supporting more efficient\nprotein utilization through the gut–muscle axis.\n\nFor brands developing products for women's vitality and long-term physical\nwellness, TWK10® offers a microbiome-based approach linked to strength,\nmovement, and everyday performance.\n\nClinical Probiotics Conquer Women's Joint, Intimate, Metabolic Health\n\nAt Vitafoods Europe 2026, SynbioTech will feature a broader portfolio of\nprobiotic and postbiotic solutions addressing the interconnected wellness\nneeds of aging women.\n\nABKefir®, a symbiotic kefir-derived blend of seven strains produced via\npatented SYNTEK™ fermentation, is supported by two clinical studies and has\ndemonstrated relief across multiple gastrointestinal symptoms including\nconstipation, bloating, and abdominal pain.\n\nSynForU® HerCare, a six-strain probiotic blend with the clinical study\nshowing a 44% reduction in VVC symptoms, 36% reduction in emotional stress,\nand a meaningful shift in vaginal microbiota toward Lactobacillus dominance,\naddresses the growing burden of recurrent vaginal infections affecting an\nestimated 138 million women annually. \n\nLDL557™, a postbiotic (L. delbrueckii subsp. lactis LDL557) targeting the\ngut–joint axis, has shown preclinical results of up to 80% reduction in\ncartilage matrix loss and 70% reduction in joint structural damage, supporting\nits potential as a next-generation joint health solution beyond conventional\napproaches.\n\nSynForU® ReMain, a two-strain probiotic blend (L. paracasei LPC1411 and L.\nplantarum LP1410) with clinical evidence showing 5.0% reduction in creatinine\nand 5.2% improvement in eGFR, and preclinical data demonstrating reductions in\nkey uremic toxin markers including indoxyl sulfate and p-cresyl sulfate,\ntargets the emerging gut–kidney axis for proactive renal wellness.\n\nFS4722™ (L. plantarum FS4722) targets uric acid metabolism through the\ngut–liver–kidney axis, with preclinical data supporting its role in uric\nacid regulation and metabolic wellness.\n\nTogether, these solutions reflect a more integrated view of women's wellness,\naddressing the relationship between strength, mobility, gut health, intimate\ncare, metabolism, and vitality as women age.\n\n\"Women's healthy aging is no longer defined by single-function products,\" said\nSean Yang, COO of SynbioTech. \"Our portfolio brings together probiotic and\npostbiotic solutions built around specific microbiome-related pathways, from\nstrength and mobility to intimate wellness and metabolic balance. This gives\nour brand partners a science-backed foundation to develop products that\nreflect women's real wellness needs as they age.\"\n\nTranslating Microbiome Science into Formulation-Ready Solutions\n\nAt Vitafoods Europe 2026, SynbioTech will highlight how probiotic and\npostbiotic science can be translated into product concepts across capsules,\npowders, sachets, functional beverages, gummies, and other supplement formats.\n\nSynbioTech will meet with global brand owners, formulators, and industry\npartners at Booth 3G236 to discuss product development opportunities for the\nnext generation of women's wellness.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/synbiotech-to-unveil-microbiomebased-platform-for-womens-healthy-aging-at-vitafoods-europe-2026-302759334.html\n\n\n\nRica Chiang, rica.chiang@SynbioTech.com.tw\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPrepMBhxa","title":"SynbioTech To Unveil Microbiome‑Based Platform for Women's Healthy Aging at Vitafoods Europe 2026","author":"PR Newswire","ticker":"1295","created":"2026-05-01T08:00:00.029Z","tickers":["1295"],"exchange":"TPEx","article_body":"SynbioTech To Unveil Microbiome‑Based Platform for Women's Healthy Aging at\nVitafoods Europe 2026\nPR Newswire\n\nKAOHSIUNG, May 1, 2026\n\nTaiwan Innovators Bring Proven Muscle, Joint, and Kidney Probiotics to Women's\nHealthy Aging\n\nKAOHSIUNG, May 1, 2026 /PRNewswire/ -- SynbioTech, a Taiwan‑based developer\nof probiotic and postbiotic solutions, will present a portfolio of\nmicrobiome‑based ingredients targeting women's healthy aging at Vitafoods\nEurope 2026, to be held May 5–7 at Fira Barcelona Gran Via in Barcelona,\nSpain. The company will exhibit at Booth 3G236 and showcase clinical and\npreclinical evidence across applications including muscle maintenance, gut\nhealth, mobility, and metabolic balance for women's healthy aging support.\n\nAs women's health shifts from narrow claims to holistic vitality, brands are\nplacing greater emphasis on long-term strength, function, and quality of life.\n\nMarket signals already reflect this trend. According to Future Market\nInsights, the global healthy aging supplement market is estimated to grow from\nUSD 1.41 billion in 2024 to USD 2.16 billion by 2034, while Grand View\nResearch reports that the global women's health segment generated USD 38.30\nbillion in 2024 and is expected to reach USD 51.76 billion by 2030. For\nbrands, the opportunity lies at the intersection of these two trends: women's\nhealthy aging.\n\nMicrobiome Solutions for the Many Dimensions of Women's Aging\n\nAs women's health broadens beyond single-function positioning, brands are\nlooking for product concepts that reflect how wellness needs are connected.\nMuscle health, digestion, metabolism, intimate care, and mobility are often\ndiscussed separately, but for aging consumers, they increasingly shape the\nsame goal: staying active and independent for longer.\n\nThis is where microbiome science is gaining relevance. Probiotics and\npostbiotics are no longer viewed only through the lens of digestive health;\nthey are being explored for broader roles across the gut–muscle axis,\nmicrobial balance, and metabolic wellness.\n\nTWK10®: From Sports Nutrition to Active Aging\n\nA key focus of SynbioTech's showc ase will be TWK10®, the company's\nLactiplantibacillus plantarum strain known for its work in sports and active\nnutrition. TWK10® is gaining relevance in active aging, where maintaining\nmuscle mass, strength, mobility, and independence becomes increasingly\nimportant. Backed by 9 clinical studies and 27 publications, TWK10® has\ndemonstrated measurable outcomes in human trials, including:\n* 3% increase in muscle mass,\n* 13% improvement in grip strength,\n* 16.8% improvement in mobility and agility\n* 51% increase in endurance and stamina\nThe strain also doubles total amino acid absorption, supporting more efficient\nprotein utilization through the gut–muscle axis.\n\nFor brands developing products for women's vitality and long-term physical\nwellness, TWK10® offers a microbiome-based approach linked to strength,\nmovement, and everyday performance.\n\nClinical Probiotics Conquer Women's Joint, Intimate, Metabolic Health\n\nAt Vitafoods Europe 2026, SynbioTech will feature a broader portfolio of\nprobiotic and postbiotic solutions addressing the interconnected wellness\nneeds of aging women.\n\nABKefir®, a symbiotic kefir-derived blend of seven strains produced via\npatented SYNTEK™ fermentation, is supported by two clinical studies and has\ndemonstrated relief across multiple gastrointestinal symptoms including\nconstipation, bloating, and abdominal pain.\n\nSynForU® HerCare, a six-strain probiotic blend with the clinical study\nshowing a 44% reduction in VVC symptoms, 36% reduction in emotional stress,\nand a meaningful shift in vaginal microbiota toward Lactobacillus dominance,\naddresses the growing burden of recurrent vaginal infections affecting an\nestimated 138 million women annually. \n\nLDL557™, a postbiotic (L. delbrueckii subsp. lactis LDL557) targeting the\ngut–joint axis, has shown preclinical results of up to 80% reduction in\ncartilage matrix loss and 70% reduction in joint structural damage, supporting\nits potential as a next-generation joint health solution beyond conventional\napproaches.\n\nSynForU® ReMain, a two-strain probiotic blend (L. paracasei LPC1411 and L.\nplantarum LP1410) with clinical evidence showing 5.0% reduction in creatinine\nand 5.2% improvement in eGFR, and preclinical data demonstrating reductions in\nkey uremic toxin markers including indoxyl sulfate and p-cresyl sulfate,\ntargets the emerging gut–kidney axis for proactive renal wellness.\n\nFS4722™ (L. plantarum FS4722) targets uric acid metabolism through the\ngut–liver–kidney axis, with preclinical data supporting its role in uric\nacid regulation and metabolic wellness.\n\nTogether, these solutions reflect a more integrated view of women's wellness,\naddressing the relationship between strength, mobility, gut health, intimate\ncare, metabolism, and vitality as women age.\n\n\"Women's healthy aging is no longer defined by single-function products,\" said\nSean Yang, COO of SynbioTech. \"Our portfolio brings together probiotic and\npostbiotic solutions built around specific microbiome-related pathways, from\nstrength and mobility to intimate wellness and metabolic balance. This gives\nour brand partners a science-backed foundation to develop products that\nreflect women's real wellness needs as they age.\"\n\nTranslating Microbiome Science into Formulation-Ready Solutions\n\nAt Vitafoods Europe 2026, SynbioTech will highlight how probiotic and\npostbiotic science can be translated into product concepts across capsules,\npowders, sachets, functional beverages, gummies, and other supplement formats.\n\nSynbioTech will meet with global brand owners, formulators, and industry\npartners at Booth 3G236 to discuss product development opportunities for the\nnext generation of women's wellness.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/synbiotech-to-unveil-microbiomebased-platform-for-womens-healthy-aging-at-vitafoods-europe-2026-302759334.html\n\n\n\nRica Chiang, rica.chiang@SynbioTech.com.tw\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T08:00:00.081049464Z","server_sent_at_ms":1777622400081},"received_at":"2026-05-01T08:00:00.141Z","source_url":null},"analysis":{"id":"12311","press_release_id":"16526","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"SynbioTech is unveiling a microbiome-based platform targeting women's healthy aging at Vitafoods Europe 2026, focusing on holistic vitality across muscle, gut, and metabolic health.\n\nKey highlights include TWK10, showing 3% muscle mass and 51% endurance increases in trials, and SynForU HerCare, which reduced VVC symptoms by 44% in clinical studies.\n\nThe launch targets a growing market projected to reach $2.16 billion by 2034, as brands seek integrated solutions for active aging and long-term wellness.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"SynbioTech targets the growing women's healthy aging market with clinical-backed probiotic strains at Vitafoods Europe."},"keyFigures":{"customDimensions":{"hercare_vvc_reduction":"44%","remain_egfr_improvement":"5.2%","hercare_stress_reduction":"36%","twk10_endurance_increase":"51%","healthy_aging_market_2024":"USD 1.41 billion","healthy_aging_market_2034":"USD 2.16 billion","womens_health_market_2024":"USD 38.30 billion","womens_health_market_2030":"USD 51.76 billion","twk10_mobility_improvement":"16.8%","twk10_muscle_mass_increase":"3%","remain_creatinine_reduction":"5.0%","ldl557_joint_damage_reduction":"70%","ldl557_cartilage_loss_reduction":"80%","twk10_grip_strength_improvement":"13%"}},"quotedText":"Women's healthy aging is no longer defined by single-function products","namedEntities":{"people":[{"name":"Sean Yang","role":"COO"}],"products":["TWK10","ABKefir","SYNTEK","SynForU HerCare","LDL557","SynForU ReMain","FS4722"],"companies":[{"name":"SynbioTech","ticker":"1295"},{"name":"Future Market Insights","relationship":"market data source"},{"name":"Grand View Research","relationship":"market data source"}],"dollarAmounts":[{"amount":"USD 1.41 billion","context":"global healthy aging supplement market size in 2024"},{"amount":"USD 2.16 billion","context":"global healthy aging supplement market size estimate for 2034"},{"amount":"USD 38.30 billion","context":"global women's health segment revenue in 2024"},{"amount":"USD 51.76 billion","context":"global women's health segment revenue estimate for 2030"}]},"materialImpact":{"score":2,"reasoning":"Routine trade show announcement unveiling an existing product portfolio with new marketing positioning for women's healthy aging. Includes specific clinical stats but lacks immediate revenue impact or binary regulatory events."},"tickerRelevance":{"others":[],"primary":"1295"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"trade-show-marketing","sectorWeight":"biotech-consumer-health"}},"event_type":"product_launch","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"SynbioTech is unveiling a microbiome-based platform targeting women's healthy aging at Vitafoods Europe 2026, focusing on holistic vitality across muscle, gut, and metabolic health.\n\nKey highlights include TWK10, showing 3% muscle mass and 51% endurance increases in trials, and SynForU HerCare, which reduced VVC symptoms by 44% in clinical studies.\n\nThe launch targets a growing market projected to reach $2.16 billion by 2034, as brands seek integrated solutions for active aging and long-term wellness.","key_figures":{"customDimensions":{"hercare_vvc_reduction":"44%","remain_egfr_improvement":"5.2%","hercare_stress_reduction":"36%","twk10_endurance_increase":"51%","healthy_aging_market_2024":"USD 1.41 billion","healthy_aging_market_2034":"USD 2.16 billion","womens_health_market_2024":"USD 38.30 billion","womens_health_market_2030":"USD 51.76 billion","twk10_mobility_improvement":"16.8%","twk10_muscle_mass_increase":"3%","remain_creatinine_reduction":"5.0%","ldl557_joint_damage_reduction":"70%","ldl557_cartilage_loss_reduction":"80%","twk10_grip_strength_improvement":"13%"}},"named_entities":{"people":[{"name":"Sean Yang","role":"COO"}],"products":["TWK10","ABKefir","SYNTEK","SynForU HerCare","LDL557","SynForU ReMain","FS4722"],"companies":[{"name":"SynbioTech","ticker":"1295"},{"name":"Future Market Insights","relationship":"market data source"},{"name":"Grand View Research","relationship":"market data source"}],"dollarAmounts":[{"amount":"USD 1.41 billion","context":"global healthy aging supplement market size in 2024"},{"amount":"USD 2.16 billion","context":"global healthy aging supplement market size estimate for 2034"},{"amount":"USD 38.30 billion","context":"global women's health segment revenue in 2024"},{"amount":"USD 51.76 billion","context":"global women's health segment revenue estimate for 2030"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T08:01:04.683Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"trade-show-marketing","sectorWeight":"biotech-consumer-health"}},"durationMs":64115,"modelName":"glm-4.7"}}